Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy

Khatri, Hiren N; Chokshi, Nimitt V; Rawal, Shruti; Patel, Bhoomika M.; Badanthadka, Murali; Patel, Mayur M.

doi:10.1016/j.ijpharm.2020.119386

Cited by 18 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In-vivo results revealed a significant reduction in tumor volume following administration of the prepared formulation compared with a pure chemotherapeutic agent. Fascinatingly, biomarkers screening showed no hepatic and renal toxicity which increases therapeutic outcomes with minimal systemic toxicity (Khatri et al 2020 ). Likewise, Griffin and O'driscoll used mannose ligands to prepare chimeric PEGylated polymeric micelles.…”

Section: Lddsmentioning

confidence: 99%

Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons

2023

View full text Add to dashboard Cite

Lymphatic drug targeting is an effective approach for targeting immunomodulators, and chemotherapeutic drugs at a specific organ or cellular location. The cellular, paracellular, and dendritic cell trafficking machinery are involved in the lymphatic transport of therapeutic agents. The engineering of triggered and hybrid lymphatic drug delivery systems (LDDS) is a promising strategy to fight cancer metastasis and microbial pandemics. Hybrid lymphatic drug delivery systems can be tailored and developed by grafting the conventional LDDS with biological agents. Thus, hybrid LDDS could collect the benefits of conventional and biological delivery systems. Moreover, the fabrication of triggered LDDS increases drug accumulation in the lymphatic system in the response to an internal stimulus such as pH, and redox status or external such as magnetic field, temperature, and light. Stimuli-responsive LDD systems prevent premature release of payload and mediate selective drug biodistribution. This improves therapeutic impact and reduces the systemic side effect of anticancer, immunomodulatory, and antimicrobial therapeutics. This review highlights the challenges and future horizons of nanoscaled-triggered LDDS and their influence on the lymphatic trafficking of therapeutic molecules. Graphical abstract

show abstract

Section: Lddsmentioning

confidence: 99%

Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons

2023

View full text Add to dashboard Cite

show abstract

“…The combination of these two formulations was studied in vivo, and the results revealed enhanced tumor regression and decreased toxicity compared to free PTX. [ 175 ] Many significant advantages of SLNs include biocompatibility, prolonged drug release, better encapsulation, and simplicity of manufacture, which is essential to bear in mind when developing an NP formulation that aims to be the next clinically approved medication.…”

Section: Smart Lipid‐based Nanocarriersmentioning

confidence: 99%

Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions

Shahrivar,

Fakhr,

Abbasgholinejad

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer‐related deaths worldwide, and conventional treatments for the disease often fall short. Smart nanoparticles (NPs) are emerging as a promising strategy for the treatment of lung cancer, owing to their ability to selectively deliver therapeutic agents to cancer cells while minimizing off‐target effects. Smart NPs can respond to specific stimuli such as changes in pH, temperature, or enzymes, allowing them to release their cargo only when triggered. Among the various types of smart NPs, lipid‐based NPs, including liposomes, solid lipid nanoparticles, cubosomes, and extracellular vesicles, have garnered the highest interest due to their biocompatibility, low toxicity, and versatility in encapsulating a wide variety of drugs and genetic material. This review discusses the current status of smart lipid‐based NPs in lung cancer treatment, including recent advances in targeting strategies, stimuli‐responsive NPs, and combination therapies. The challenges and opportunities associated with translating smart lipid‐based NPs for lung cancer treatment into clinical applications are also discussed. This review highlights the potential of smart lipid‐based NPs to revolutionize lung cancer treatment and improve patient outcomes.

show abstract

“…Some novel biomolecules that are intensively researched upon for serving the purpose of active targeting through the bionanotechnology approach include the antibody/affibody [ 116 , 117 ], lipoproteins [ 118 ], proteins and peptides [ 119 – 121 ], pulmonary surfactant, and biosurfactant [ 122 – 126 ], vitamins and other small molecules [ 127 ]. The basic nanocarriers that can be modified using any of the aforementioned biomolecules for diverse oncological applications can be summarized as lipid-based nanoparticles (liposomes, SLNs, NLCs) [ 128 – 130 ], polymeric nanoparticles (dendrimers [ 131 – 134 ], polymeric [ 135 – 140 ], polymersomes [ 141 – 143 ], layer-by-layer nanoassembly (LBL) [ 144 , 145 ], nanosponges [ 146 – 148 ], lipid-polymeric nanoparticles [ 149 , 150 ], protein nanoparticles (casein, zein, etc.) [ 151 ], polysaccharide nanoparticles (mannosylated, chitosan, hyaluronan, fucoidan-based nanoparticles) [ 152 , 153 ], carbon nanostructures (nanotubes, graphene, fullerene, nanodiamonds [ 154 ], inorganic nanoparticles (SPIONs, upconversion nanoparticles, silver nanoparticles, gold nanoparticles, mesoporous silica nanoparticles), and quantum dots [ 155 – 159 ].…”

Section: Nanobioengineering and Bio-nanotools: Types And Sub-typesmentioning

confidence: 99%

Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers

Rawal

Patel

2021

Nano-Micro Lett.

Self Cite

View full text Add to dashboard Cite

Lung cancer is a complex thoracic malignancy developing consequential to aberrations in a myriad of molecular and biomolecular signaling pathways. It is one of the most lethal forms of cancers accounting to almost 1.8 million new annual incidences, bearing overall mortality to incidence ratio of 0.87. The dismal prognostic scenario at advanced stages of the disease and metastatic/resistant tumor cell populations stresses the requisite of advanced translational interdisciplinary interventions such as bionanotechnology. This review article deliberates insights and apprehensions on the recent prologue of nanobioengineering and bionanotechnology as an approach for the clinical management of lung cancer. The role of nanobioengineered (bio-nano) tools like bio-nanocarriers and nanobiodevices in secondary prophylaxis, diagnosis, therapeutics, and theranostics for lung cancer management has been discussed. Bioengineered, bioinspired, and biomimetic bio-nanotools of considerate translational value have been reviewed. Perspectives on existent oncostrategies, their critical comparison with bio-nanocarriers, and issues hampering their clinical bench side to bed transformation have also been summarized.

show abstract

Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy

Cited by 18 publications

References 43 publications

Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons

Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons

Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions

Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers

Contact Info

Product

Resources

About